Please ensure Javascript is enabled for purposes of website accessibility

Is Danger Lurking in Dendreon's Future?

By Brenton Flynn and Dave Williamson - Nov 6, 2012 at 4:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What investors need to know.

No stock sums up biotech investing quite like Dendreon (NASDAQ: DNDN), the company behind a novel prostate cancer treatment called Provenge. In what amounts to a case study on unchecked optimism, Dendreon shares were still flying high just over a year ago on exuberant sales projections. Then things took a turn for the worse. Management pulled revenue guidance, and shares collapsed.

Before the collapse occured, management used a soaring outlook, and stock price, as an opportunity to raise cash. However, that money was raised in a way that might come back to haunt it in the not-too-distant future. Follow along in the following video as Brenton and David go into more detail on a future obligation that potential investors must be aware of.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Medivation, Inc. Stock Quote
Medivation, Inc.
Johnson & Johnson Stock Quote
Johnson & Johnson
$173.94 (-0.89%) $-1.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.